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Abstract 
Cisplatin is a widely used chemotherapeutic agent for the treatment of various 
malignancies. However, its maximum dose is often limited by severe ototoxicity. 
Cisplatin ototoxicity may require the production of reactive oxygen species (ROS) in 
the inner ear by activating enzymes specific to the cochlea. Molecular hydrogen was 
recently established as an antioxidant that selectively reduces ROS, and has been 
reported to protect the central nervous system, liver, kidney and cochlea from oxidative 
stress. The purpose of this study was to evaluate the potential of molecular hydrogen to 
protect cochleae against cisplatin. We cultured mouse cochlear explants in medium 
containing various concentrations of cisplatin and examined the effects of hydrogen gas 
dissolved directly into the media. Following 48-h incubation, the presence of intact 
auditory hair cells was assayed by phalloidin staining. Cisplatin caused hair cell loss in 
a dose-dependent manner, whereas the addition of hydrogen gas significantly increased 
the numbers of remaining auditory hair cells. Additionally, hydroxyphenyl fluorescein 
(HPF) staining of the spiral ganglion showed that formation of hydroxyl radicals was 
successfully reduced in hydrogen-treated cochleae. These data suggest that molecular 
hydrogen can protect auditory tissues against cisplatin toxicity, thus providing an 
additional strategy to protect against drug-induced inner ear damage. 
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Highlights 
 The use of hydrogen molecule as an antioxidant for inner ear protection is 
described. 
 Cisplatin induced free radical formation and auditory hair cell loss in the cochlea.  
 Hydrogen gas increased the number of surviving hair cells after cisplatin damage.  
 In hydrogen-treated cochleae, formation of hydroxyl radicals was reduced. 
 
Keywords: reactive oxygen species; hydroxyl radical; cochlea; hearing loss; 
antioxidant; chemotherapy 
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Introduction 
Cisplatin (cis-diammine-dichloroplatinum (II) / CDDP) is a widely used 
chemotherapeutic agent in pediatric and adult oncology protocols. Unfortunately, hearing 
loss is a major dose-limiting side effect that presents as bilateral, irreversible and 
progressive sensorineural hearing loss, which leads to a decrease in quality of life of 
cancer patients [12]. Up to 93% of patients receiving cisplatin chemotherapy will 
experience ear-related symptoms, however, no treatment is currently available for 
cisplatin-induced ototoxicity [17]. In the inner ear, cisplatin targets the organ of Corti, 
spiral ganglion neurons (SGNs), the stria vascularis, and spiral ligament [2]. Once 
cisplatin enters the cell, it induces cell death mainly by oxidative stress and inflammation 
[18]. Previously, we have shown that this phenomena is caused by apoptotic but not 
necrotic cell death [15]. 
Molecular hydrogen (hydrogen gas) has been recently established as a potent 
antioxidant that selectively reduces the hydroxyl radical, and has been shown to reduce 
the cerebral infarction volume after ischemia in rats [8, 9]. Subsequently, the use of 
hydrogen as a therapeutic medical gas was pursued in diverse models of disease including 
central nervous system, cardiovascular, gastrointestinal and sensory organs [3-5]. 
Alleviation of side effects during cancer therapy with hydrogen was also studied using 
various methods of hydrogen delivery [3, 6]. An animal study has demonstrated that 
consumption of hydrogen-rich water efficiently mitigates cisplatin-induced renal side 
effects by reducing oxidative stress while retaining the anti-tumor capacity of the drug 
[7]. 
This present ex vivo study tested the hypothesis that molecular hydrogen protects 
against cisplatin-induced cochlear impairment. Using a hydrogen gas-saturated culture 
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media, we demonstrated that hydrogen alleviated ROS-induced ototoxicity, suggesting 
that molecular hydrogen has the potential to serve as an antioxidant for the treatment of 
cochlear damage. We also evaluated generated hydroxyl radicals by fluorescence 
emission of 2-[6-(4′-hydroxy)phenoxy-3H-xanthen-3-on-9-yl] benzoate (hydroxyphenyl 
fluorescein / HPF) in the spiral ganglion and demonstrated that ROS production was 
successfully reduced in the hydrogen-treated cochlea. 
 
Materials and methods 
Animals 
In this study, ICR mice (Japan SLC, Hamamatsu, Japan) were cared for in the 
Institute of Laboratory Animals of the Kyoto University Graduate School of Medicine. 
The Animal Research Committee of the Kyoto University Graduate School of Medicine 
approved all experimental protocols, which were performed in accordance with the 
National Institutes of Health (NIH) Guidelines for the Care and Use of Laboratory 
Animals. 
 
Cochlear explant culture 
Details for cochlear organotypic cultures were described elsewhere [4]. Briefly, 
organ of Corti (OC) explants were harvested from postnatal day 2 (P2) ICR mice. The 
explants were placed on glass-mesh inserts and cultured initially in serum-free modified 
Eagle’s medium supplemented with 3 g/l glucose and 0.3 g/l penicillin G. In total, 20 
cochlear explants were used in a single culture, and at least three independent cultures 
were performed for each condition. Because the hair cells in the apex are resistant to free 
radicals [14], basal turns of the cochlea were used in this study. 




The explants were transferred to medium containing cisplatin (Maruko, Yakult, 
Japan) at concentrations of 0, 10, 20, or 40 µM with six to nine cochleae incubated at each 
concentration. The cultures were maintained for 48 h. At the end of the culture period, the 
samples were fixed for 15 min in 4% paraformaldehyde in 0.1 M phosphate buffer (pH 
7.4). The specimens were then rinsed with PBS and incubated in 1% bovine serum 
albumin with 0.2% Triton X-100 for 30 min before incubation with primary rabbit 
polyclonal antibodies against myosin VIIa (1:500; Proteus Bioscience Inc., Ramona, CA). 
Alexa Fluor 568-labeled goat anti-rabbit IgG (1:200; Invitrogen) was used as the 
secondary antibody. Specimens were then incubated in Alexa Fluor 488-labeled 
phalloidin (1:250; Invitrogen) in PBS to visualize the stereocilia. The specimens were 
examined with a Nikon Eclipse E600 fluorescence microscope (Nikon, Tokyo, Japan) or 
a Leica TCS-SP2 laser scanning confocal microscope (Leica Microsystems Inc., Wetzlar, 
Germany), and images were captured with a digital camera (Leica DC330). 
 
Hydrogen treatment of cultured cells 
To evaluate the efficacy of molecular hydrogen for cochlear protection, explants 
after initial culture were incubated in an airtight container (Chopla Industries, Inazawa, 
Japan) with reduced-CO2-dependent media, i.e., MEM and Leibovitz’s L-15 media 
(Invitrogen) mixed in a 1:1 ratio at 37°C in a humidified 100% air atmosphere with 
different concentrations of cisplatin, with or without molecular hydrogen. Hydrogen gas 
was dissolved directly into the media, and a high content of dissolved hydrogen (1.3 ± 0.1 
mg/L) was confirmed using a hydrogen electrode (Model M-10B2; Able Corporation, 
 | 7 
 
Tokyo, Japan). At the end of the experiments, the explants were fixed and stained with 
myosin VIIa antibody and phalloidin to evaluate hair-cell survival. 
 
Cell survival assay 
Each cochlea was examined on a Leica TCS-SP2 confocal microscope with a 40x 
objective, using excitation and emission filters of 488 and 510 nm, respectively. To 
quantify hair-cell loss in the cochlea after different treatments, inner hair cells (IHCs) and 
outer hair cells (OHCs) were blindly counted over a 100-µm-long stretch of the auditory 
epithelia, in two separate randomly selected regions of the basal turn in each cochlear 
explant (totaling 200 µm). For each treatment, six to nine explants were evaluated. 
 
Detection of ROS by fluorescent indicators 
The spiral ganglion, spiral limbus, and organ of Corti were isolated en bloc from P2 
ICR mouse cochlear capsule referred to as an ‘organotypic’ culture. The cultures were 
then transferred to glass-mesh inserts in an airtight container with or without molecular 
hydrogen and 40 µM cisplatin. After 100 minutes, the tissues were treated with 30 µM 
HPF (Daiichi Pure Chemicals Co., Tokyo, Japan) for 20 min to detect cellular hydroxyl 
radicals. Fluorescent images were captured with a Leica TCS-SP2 confocal microscope, 
using a 40x objective (imaged area 280 µm x 280 µm). All images were taken with the 
same laser intensity, detector gain, and offset values. For each cochlea, consecutive 100 
spiral ganglion cells were measured in a randomly selected 7.82 x 104 µm2 area of the 
basal turn for HPF fluorescence intensity. This experiment was independently repeated 
six times. 
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Statistical analysis 
The overall effects on the hair-cell number and the HPF staining intensities were 
analyzed by two-way factorial analysis of variance (ANOVA) using the Statcel2 
application (OMS Publishing, Saitama, Japan). P values <0.05 were considered to be 
statistically significant. For interactions that were found to be significant, multiple paired 
comparisons were analyzed using the Tukey-Kramer test. 
 
Results 
Cisplatin induced dose-dependent hair-cell loss  
Initially, we established a dose–response relationship between cisplatin 
concentration and its toxic effect on hair cells. The addition of cisplatin to cultures for 48 
h significantly reduced the hair-cell numbers in both the IHC and OHC regions, with the 
effect being more severe in the latter (Fig. 1A, C, E, and G). The hair-cell density 
decreased depending on the concentrations of cisplatin, and few could be detected in the 
auditory epithelia cultured in 40 µM cisplatin.  
 
Protective effect of hydrogen supplementation 
Subsequently, we assessed the potential of hydrogen to protect against 
cisplatin-induced ototoxicity by administering 0, 10, 20, or 40 µM cisplatin to samples 
cultured in hydrogen-saturated media in an airtight environment. The addition of 10, 20 
or 40 µM cisplatin destroyed 1.9 ± 15.1%, 13.0 ± 14.0% or 62.0 ± 23.0% of the IH cells 
and 63.6 ± 15.1%, 89.1 ± 4.1% or 90.0 ± 11.1% of the OH cells, respectively (mean ± 
SEM). When hydrogen was added, the cell loss rates were 1.7 ± 21.9%, 12.7 ± 23.5% or 
39.0 ± 11.2% for IHC and 46.1 ± 3.4%, 68.4 ± 11.4% or 87.2 ± 14.7% for OHC, 
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respectively. The addition of hydrogen increased both IHC and OHC survival, with a 
substantial number of inner hair cells surviving even at the highest cisplatin dose (40 µM; 
Fig. 1I). Two-way factorial ANOVA showed that hydrogen had a significant effect on the 
numbers of surviving IHCs (P = 0.0008) and OHCs (P = 0.0005) in cisplatin-damaged 
cochleae. However, post-hoc analysis could not identify any individual factor responsible 
for these statistically significant changes. No significant interaction between the two 
factors (concentration of cisplatin and presence of hydrogen) was found. 
 
ROS production in the cochlea was attenuated by molecular hydrogen 
To investigate the mechanism by which hydrogen alleviated cochlear damage, we 
further measured ROS production in the cultured auditory epithelia (Fig. 2). HPF is a 
novel reagent that was developed to directly detect certain highly reactive oxygen species 
(hROS) [13]. Although HPF itself shows little fluorescence, it selectively and 
dose-dependently reacts with hROS, such as hydroxyl radicals and peroxynitrite, to 
generate the strongly fluorescent compound fluorescein. In cochlear organotypic cultures 
treated with 40 µM cisplatin for 100 min and in the absence of molecular hydrogen, HPF 
signals increased, indicating that cisplatin induced the production of hROS. In the spiral 
ganglion, the intensity of the HPF fluorescence after treatment with 40 µM cisplatin was 
1.19-fold greater than that in the absence of cisplatin (Fig. 2A, C). In contrast, with 
hydrogen, HPF fluorescence intensity increased by 1.07-fold, which indicates that hROS 
production was suppressed after hydrogen application. Two-way ANOVA showed that 
hydrogen had a significant effect on the formation of hydroxyl radicals (P = 0.036). 
 
Discussion 
 | 10 
 
The exact mechanism for cisplatin ototoxicity still remains unclear. However, it 
appears that cisplatin causes apoptosis by binding DNA, activating the inflammatory 
cascade as well as generating oxidative stress in the cell [17]. Cisplatin in the cochlea 
causes the formation of reactive oxygen radicals, especially free radicals, such as 
superoxide anions. Cisplatin ototoxicity is also believed to be related to malfunction of 
the antioxidant system. Derangement of the antioxidant defense system causes an 
increase in lipid/DNA peroxidation, and therefore leads to apoptosis of hair cells, support 
cells, the stria vascularis, and auditory nerves [16]. 
We have previously reported the effects of hydrogen gas on cochlear and vestibular 
hair cells against ROS toxicity with antimycin A, which inhibits the mitochondrial 
electron transport complex III and produces ROS [4] [15]. In this study, we applied this 
same method to cisplatin-damaged cochlea. Our cochlear culture system, along with 
chemiluminescence detection, was highly useful in screening for antioxidant drugs, 
because ROS was directly produced in the cochlear tissue and the antioxidative effect can 
easily be measured by counting the number of surviving cells. In this study, quantitative 
assessment of hair cell loss caused by cisplatin showed a dose-dependent effect, and 
treating the cultures with molecular hydrogen significantly influenced the dose response 
for hair cell loss, indicating that molecular hydrogen has a protective effect on the hair 
cells against cisplatin toxicity. Obviously the situation ex vivo differs in many respects 
from that in vivo, with direct access of the drug to the apical surface of the hair cell or 
tissues like stria vascularis and spiral ligament were excised in the dissection process. 
Nonetheless this culture system is at least one in which morphological responses to 
cisplatin can be rapidly observed under strictly controlled conditions. 
We also investigated the mechanisms by which molecular hydrogen protected hair 
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cells from damage in the cochlea. The direct measurement of ROS in the cochlear tissue 
was made possible when HPF was used. Our results demonstrated that molecular 
hydrogen reduced cellular ROS in the auditory tissue. Nakashima-Kamimura showed 
that consuming hydrogen water ad libitum alleviates ROS production in the kidney, thus 
preventing acute renal injury, reduced body weight loss and mortality after systemic 
cisplatin administration [7]. 
Hydrogen is one of the most abundant and well-known molecules. Inhalation of 
molecular hydrogen gas has been used to prevent decompression sickness in divers, has 
shown a good safety profile, and has been approved by the US Food and Drug 
Administration for the treatment of several different diseases [3, 8]. Molecular hydrogen 
is a mild but potent antioxidant with certain unique chemical properties; being a gas 
allows it to be permeable to cell membranes, and it can therefore directly target cellular 
organelles. This feature is especially favorable in inner ear medicine, because many 
therapeutic compounds are blocked by the blood–cochlear barrier and cannot reach the 
organ of Corti and cochlear hair cells [1]. There are several ways to intake or consume 
hydrogen, including inhaling hydrogen gas, drinking hydrogen-dissolved water, taking a 
hydrogen bath, injecting hydrogen-dissolved saline, and increasing the production of 
intestinal hydrogen by bacteria [9, 10]. Lin et al.[5] utilized hydrogen-dissolved drinking 
water to treat noise-induced hearing loss. Another possible approach is injecting 
hydrogen-dissolved saline to the middle ear, which allows the dissolved hydrogen to 
immediately penetrate to the cochlea.  
Previous studies have aimed at evaluating various compounds such as antioxidants, 
anti-inflammatories, caspase inhibitors and calcium channel blockers against the toxicity 
caused by cisplatin in the inner ear with variable degrees of protection [11, 17]. The 
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greatest level of otoprotection seems to arise from antioxidant treatments, however, the 
ideal protective agent has not yet been found [17]. Therefore, many researchers have 
suggested a combination of antioxidants to pursue maximum effect and safety [11]. Our 
present study proposes hydrogen as an additional approach to protect against 
drug-induced inner ear damage. 
 
Conclusions 
This study demonstrated that molecular hydrogen protected cochlear hair cells 
against cisplatin-induced toxicity. Hydrogen decreased oxidative stress by scavenging 
ROS and protected cochlear tissue against cisplatin-induced oxidative stress. These 
results have prompted us to perform in vivo studies to determine whether treatment with 
molecular hydrogen might exert a beneficial effect on cisplatin-damaged cochleae and 
promote hearing recovery.  
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Figure 1: Effect of molecular hydrogen (H2) on the survival of cochlear hair cells. (A–
H) Photomicrographs of phalloidin-labeled cochlear cultures treated with 0 
(A and B), 10 (C and D), 20 (E and F), and 40 µM (G and H) cisplatin (Cis), 
with (B, D, F and H) or without (A, C, E and G) hydrogen gas. IHCs, inner 
hair cells; OHCs, outer hair cells. Note that cisplatin effects are greater on 
inner OHCs than IHCs. Bar, 10 µm. (I-H) Hair-cell counts in 
hydrogen-treated cultures. After a 48-h culture with cisplatin, IHCs (I) and 
OHCs (J) were counted. Black box symbols represent the counts from 
control cultures without hydrogen, and white circles represent those from 
cultures with molecular hydrogen. Two-way factorial ANOVA showed 
molecular hydrogen significantly attenuated the loss of IHCs (P = 0.0008) 
and OHCs (P = 0.0005) in cisplatin-damaged cochleae. Bars represent 
standard errors. 
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Figure 2: Molecular hydrogen (H2) reduced reactive oxygen species (ROS) formation. 
(A, B) Photomicrographs of HPF in spiral ganglion cultures treated with 40 
µM cisplatin for 100 min with (B) or without (A) hydrogen gas (H2). Bar, 
20 µm. (C) Relative HPF fluorescence intensity in the spiral ganglion cells. 
Black box symbols represent the counts from control cultures without 
molecular hydrogen, and white circle symbols represent those from cultures 
with molecular hydrogen (n = 6, 100 cells were measured for each culture). 
The relative HPF fluorescence intensity in the spiral ganglion increased in 
the presence of cisplatin but declined significantly with the addition of 
hydrogen gas (P = 0.036). The data shown are the relative intensities of 
HPF staining ± SE (n = 6 cochleae). Bars represent standard errors. 
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